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Background 
Fever and neutropenia (FN) clinical decision rules (CDRs) are recommended to help distinguish 
children with cancer at high and low risk of severe infection. The aim of this study was to 
validate existing pediatric FN CDRs, designed to stratify children with cancer at high or low risk 
of serious infection or medical complication. 
Methods 
Pediatric CDRs suitable for validation were identified from a literature search. Relevant data 
were extracted from an existing dataset of 650 retrospective FN episodes in children with cancer. 
The sensitivity and specificity of each of the CDR were compared with the derivation studies to 
assess reproducibility. 
Results 
Six CDRs were identified for validation: two were designed to predict bacteremia and four to 
predict adverse events. Five CDRs exhibited reproducibility in our cohort. A rule predicting 
bacteremia had the highest sensitivity (100%; 95% confidence interval (CI) 93-100%) although 
poor specificity (17%) with only 15% identified as low risk. For adverse events, the highest 
sensitivity achieved was 84% (95% CI, 75-90%) with specificity of 29% and 27% identified as 
low risk. A rule intended for application after a 24-hour period of inpatient observation yielded a 
sensitivity of 80% (95% CI, 73-86) and specificity of 46%, with 44% identified as low-risk.  
Conclusion 
Five CDRs were reproducible although not all can be recommended for implementation because 
of either inadequate sensitivity or failure to identify a clinically meaningful number of low-risk 
patients. The 24-hour rule arguably exhibits the best balance between sensitivity and specificity 
in our population. 
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INTRODUCTION 
The risk of infection in the setting of chemotherapy-induced neutropenia, heralded by fever, 
remains an unavoidable complication of the treatment of childhood cancer. Treatment strategies 
for fever and neutropenia (FN) that are WDLORUHGWRDQLQGLYLGXDO¶Vlikelihood of severe infection, 
by incorporating risk stratification, are well described.(1) To help differentiate children at low 
and high risk of severe infection, pediatric FN clinical decision rules (CDRs) have been 
recommended as an important adjunct to the risk stratification process.(2) Children accurately 
identified as low-risk may benefit from reduced intensity antibiotic therapy and early hospital 
discharge, while additional supportive care measures and heightened vigilance may avoid 
clinical deterioration in high-risk patients.(3) 
There are four key components to CDR development: derivation, internal validation, external 
validation and implementation and impact analysis.(4) Before a CDR, especially one targeting 
pediatric FN, can be implemented into practice it should undergo evaluation in a population 
external to the derivation dataset to ensure it is safe and reliable.(5) While many of the pediatric 
FN CDRs that have undergone external validation show some reproducibility, most result in 
lower sensitivity compared to the derivation study.(6-10) This highlights the importance of 
detailed local external validation to provide clinicians with a realistic expectation of the 
predictive performance of a CDR in their own population. Such validations will identify CDR 
limitations and should guide implementation of low-risk treatment programs that incorporate 
safeguards against potential failures of the CDR. 
Using an existing local dataset of consecutive episodes of outpatient onset FN, retrospectively 
collected to validate the Prediciting Infectious ComplicatioNs in Children with Cancer 
(PICNICC) CDR, the aim of this study was to validate additional published pediatric FN CDRs 
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designed to stratify children with cancer or hematologic malignancy at high or low risk of 
serious infection or medical complication.(10) The sensitivity, specificity, positive predictive 
value and negative predictive value of each of these rules applied to our retrospective dataset was 
compared with the derivation studies.  
METHODS 
Identification of clinical decision rules for validation 
A list of published pediatric CDRs was compiled from two systematic reviews.(6, 11) A PubMed 
search for relevant pediatric CDRs published since these reviews using the search terms: (fever 
OR febrile OR sepsis) AND (neutropenia or neutropenic) AND (child OR children OR paediatric 
OR pediatric) was also conducted (non-English studies and abstracts were excluded). The date of 
the search was 18th April 2016. Studies were excluded if there was insufficient information 
available from the existing retrospective dataset to validate the rule or if no rule was described. 
Rules that included presence of CVAD as predictor of outcome were also excluded as 95% of 
children in the existing dataset had a CVAD and this was deemed a priori as non-
discriminatory.(10) 
Data collection 
External validation was performed using an existing local dataset of retrospectively identified 
episodes of outpatient-onset FN in children and adolescents with cancer or hematological 
malignancy.(10) This local dataset will be herein described as validation cohort. Detailed 
methodology for patient episode identification and data collection is described elsewhere.(10) 
Briefly, consecutive episodes of outpatient-onset FN in children and adolescents (age <19 years) 
with cancer and receiving chemotherapy or hematopoetic stem cell transplant (HSCT) at The 
5R\DO&KLOGUHQ¶V+RVSLWDO (RCH), Melbourne were included in the study (November 2011 to 
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June 2015). Demographic, FN episode and clinical outcome data were obtained from electronic 
records and entered into REDCap database.(12) Data were collected by a research assistant 
blinded to the CDRs included in this analysis. Patients were excluded if they were already 
receiving empiric or targeted treatment antibiotics or onset of the FN episode occurred in 
hospital.  
Definitions 
Fever was defined as a single tympanic temperature greater than, or equal to, 38 degrees Celsius 
and neutropenia was defined as an absolute neutrophil count less than 1000/mm3. Bacteremia 
was defined as a recognized pathogen (including viridans group streptococci in the setting of 
mucosal barrier injury or neutropenia) cultured from one or more blood cultures or common 
commensal bacteria cultured from two or more blood cultures drawn on separate occasions.(13)  
For validation, the variable or outcome definition used in the derivation study was applied to our 
validation cohort. $QH[FHSWLRQWRWKLVZDVµbacteremia¶ZKHre the above international 
consensus definition was applied to avoid incorrectly attributing single positive blood culture 
with a common commensal as a true bacteremia. Where no definition was provided, variables or 
outcomes followed international consensus recommendations.(13, 14) The date and time 
bacteremia episodes were known were extracted from the electronic pathology database. For all 
other clinical and microbiologically defined infections (MDIs) and for medical complications 
such as intensive care unit (ICU) admission, the date and time the infection or event was 
documented in the medical record were used. 
Statistical analysis 
The sensitivity, specificity, positive predictive value (PPV) and negative predictive values (NPV) 
for each rule were calculated in our validation cohort using both the inclusion and exclusion 
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criteria from our existing dataset(10) and those criteria restricted to that described by the 
derivation studies. Confidence intervals around sensitivity and specificity were calculated using 
hybrid Wilson/Brown method. To ensure consistency, confidence intervals from the derivation 
studies were recalculated from available data. For rules that stratified patients into more than 2 
groups (ie low, intermediate and high-risk), we combined intermediate and low risk into a single 
low-risk group. The sensitivity and specificity of the Swiss Pediatric Oncology Group (SPOG) 
rule was determined by combining the information on episodes with MDI known at day 2 with 
the results of prediction on the remaining episodes.(9) 
Continuous data were presented as median and interquartile range. )LVKHU¶V exact test was used 
to estimate P-values for categorical data, including comparison of sensitivity and specificity 
between derivation and validation cohorts. The Newcombe-Wilson test with continuity 
correction was used for difference between proportions. A CDR was considered reproducible if 
there was no significant difference in either the sensitivity or specificity between the derivation 
and validation cohorts.  All tests were 2-tailed, and a P value of <0.05 was considered to be 
statistically significant. 
RESULTS 
A total of 21 potentially relevant studies describing pediatric FN CDRs or risk factors for severe 
infection were identified in published systematic reviews(6, 11) and a further six were identified 
in our search of the literature.(15-20) Of these 27 studies, six described CDRs that were suitable 
for validation in our dataset.(9, 21-25) Eleven could not be validated, as there was insufficient 
information available from the existing dataset.(16, 21, 26-34) A further eight studies described 
individual variables for infection or adverse outcome in the absence of a defined rule.(17-20, 35-
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38) In the remaining two, a CVAD was used as a predictor of outcome(39) and validation of the 
PICNICC CDR using this dataset had already been completed.(10) 
Details of study design and demographic data from the validation cohort and the included 
derivation studies are available in Table, Supplemental Digital Content 1, 
http://links.lww.com/INF/C843. Where sufficient data were available for comparison, there was 
no significant difference in sex, proportion with relapsed disease or death in the validation cohort 
compared to any of the derivation studies. There were significantly more patients with 
hematologic malignancy in the validation cohort compared to the Alexander et al and Rackoff et 
al derivation studies.(22, 25) Bacteremia occurred in significantly fewer FN episodes in our 
validation cohort compared to the Swiss Pediatric Oncology Group (SPOG), Baorto et al and 
Rackoff et al derivation studies.(9, 23, 25)  
Table 1 provides details of the inclusion and exclusion criteria as well as description of the CDR 
variables and predicted outcomes. A different definition of fever, albeit slightly, was used in all 
six studies and almost all excluded patients with HSCT. The number of clinical variables 
included in the CDRs ranged from one to nine (1 variable in 2 CDR, 2 in 1, 4 in 2 and 9 in 1). 
Two CDRs were designed to predict bacteremia only, of which a definition was provided for 
only one.(23, 25) The remaining four CDRs predicted composite outcomes encompassing a 
varying combination of microbiological infection, sepsis, pneumonia, severe medical 
complication or death. 
Results of the sensitivity, specificity, PPV and NPV analyses for each CDR are shown in Table 
2. The clinical impact of each rule was calculated using both the existing dataset inclusion 
criteria (validation cohort) and the derivation study inclusion criteria (restricted validation 
cohort). Notably, for each of the six rules, there was very little difference in the validation results 
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obtained using the different inclusion criteria with broad overlap of the 95% confidence intervals 
for all results (Figures 1 and 2). Bacteremia was observed in significantly fewer FN episodes in 
our validation cohort compared to the two derivation studies that specifically investigated this 
outcome.(23, 25) (Table 2) For the remainder, there was no significant difference in the 
proportion of patients with the specific outcome investigated. 
A direct comparison of sensitivity and specificity between the derivation studies and both the 
validation cohort and restricted validation cohort is also shown in Table 2.  There was a 
significant difference in both sensitivity and specificity between the Hakim et al derivation and 
both validation cohorts.(21) For the remaining five CDRs, there was no difference between 
sensitivity for one CDR (Klaassen), specificity in one (SPOG) or both sensitivity and specificity 
in three (Rackoff, Baorto and Alexander).(22, 23, 25) The CDR with the highest sensitivity in 
the local validation cohort was developed by Baorto et al, followed by the Klaassen and SPOG 
CDRs.(9, 23, 24) Of these three, the SPOG CDR had the greatest specificity at 46%, correctly 
identifying 86% of low-risk patients in the local validation cohort.(9) 
DISCUSSION 
Using a pre-existing dataset we were able to externally validate six pediatric CDRs designed to 
predict bacteremia or adverse outcomes in children with cancer and FN. Reproducibility was 
observed in five of the CDRs, with no significant difference in both sensitivity and specificity 
between the derivation and validation cohorts in three of these.(22, 23, 25) Although often 
attributed as a cause of discordant derivation and validation study results, we also showed that 
using inclusion and exclusion criteria that varied to that of the derivation study appeared to have 
little impact. 
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7KUHHRIWKHUHSURGXFLEOHUXOHVZHUHGHVLJQHGWRSUHGLFWDFRPSRVLWHRXWFRPHRIµDGYHUVH
outcome¶ RUµVHULRXVLQIHFWLRQ¶(9, 22, 24) While the definition for these composite outcomes 
varied between studies, all three included at least bacteremia, other bacterial infection and death. 
The CDR by Klaassen et al had the highest sensitivity in validation cohort (84%) but the lowest 
specificity (28%).(24) 7KHLQFOXVLRQRIWKHVXEMHFWLYHRXWFRPHRIµOLIH-threatening complication 
DVMXGJHGE\WKHWUHDWLQJSK\VLFLDQ¶PD\KDYHFRQWULEXWHGWRWKHORZHUVHQVLWLYLW\REVHUYHGLQ
the validation results of the SPOG and Alexander CDR.(9, 22) Despite this, the SPOG rule, in 
particular, produced a sensitivity of up to 80% with a specificity of 46%, correctly identifying 
86% of low-risk patients. This CDR is unique in that it is applied after a 24-hour period of 
inpatient observation. 
The remaining two reproducible CDRs in our validation cohort were designed to predict 
bacteremia.(23, 25) Notably, the proportion of bacteremia episodes in the local validation cohort 
(9%) was significantly lower than both these derivation studies. This difference can be attributed 
to the strict exclusion of common commensals identified on single blood cultures to avoid 
incorrectly attributing these as a true bacteremia.(35). The rule developed by Baorto et al 
produced the highest sensitivity and PPV in the validation cohort, approaching 100%. Not 
surprisingly the specificity was poor, with very few episodes being identified as low risk. These 
data suggest that implementation of this CDR in our population, while reassuring given the very 
high sensitivity, would be difficult to justify as only 33 out of 177 patients per year would 
qualify as low risk and therefore appropriate for consideration of reduced intensity therapy. 
While this is the first study to validate these international CDRs in Australia, five have 
previously undergone validation in populations external to the derivation studies.(9, 22-25) Most 
of these validation studies demonstrate at least some degree of overlap in confidence intervals for 
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either sensitivity or specificity suggesting validity.(7-9, 40-42) The three rules derived in the 
USA(22, 23, 25) have been shown to be effective in Europe and the UK(7, 9, 40, 42) and the 
Canadian rule(24) in Europe and USA.(7, 9, 41) However, until now, the SPOG rule has not 
been tested outside of Europe.(8)   
The CDRs included in this study were validated using an existing dataset designed to validate the 
PICNICC CDR.(15) This rule was developed from an individual participant data meta-analysis 
and included data from four of the rules validated in this study.(9, 21, 22, 24) For the prediction 
of MDI, the recalibrated PICNICC rule did not perform as well in our population as compared to 
the derivation study with a sensitivity and specificity of 78.4% and 39.8%, respectively.(10) 
However when using methodology described by Ammann et al for the SPOG rule, the sensitivity 
of the PICNICC rule improved to 88% further highlighting the importance of an overnight period 
of observation.(9) 
Although this study was performed using an existing, retrospective dataset, it includes a 
contemporary cohort of consecutive episodes of FN. Given the reliance on the existing dataset, 
sample size calculations were not performed. For validation of a CDR in a new population, a 
sample size that includes 100 outcome events and 100 non-outcome events has been 
recommended.(43) Based on this, an appropriate sample size was achieved for validation of three 
of the six CDRs, of which two predicted adverse outcome(9, 22) and one predicted significant 
bacterial infection.(24) With regard to validation of the SPOG rule, it is possible that the date and 
time that non-bacteraemia microbiologically and clinically documented infections, as well as 
medical complications such as admission to ICU, were known were earlier than what was 
documented in the medical records. This would have underestimated the sensitivity of the SPOG 
rule that takes into account the number of infections or medical complications known at time of 
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assessment. Our study is unique in that it compared validation results using differing inclusion 
criteria. The similarities in results between the two validation cohorts suggests that the impact of 
differences in inclusion and exclusion criteria between derivation and validation studies may 
have been overstated, although this will vary study to study.  
 The rationale for risk prediction in FN is to tailor treatment strategies according to the likelihood 
of having a documented infection or adverse outcome. This will avoid over treatment of children 
with viral illness or non-infective causes of fever and, conversely, enable targeted treatment and 
observation strategies for high-risk patients to avoid severe complication such as late onset 
sepsis, ICU admission and death. A systematic review of oral and outpatient antibiotic regimens 
for children with low-risk FN which analyzed data from 13 randomized controlled trials and 24 
prospective observational studies concluded that both oral antibiotics and outpatient therapy are 
safe alternatives to standard care.(1) The rate of modification from reduced intensity therapy 
back to standard inpatient care appears to be affected by the time of discharge with a significant 
reduction in requirements for pathway modifications when patients were discharged after 48 
hours compared to immediately (2.2% versus 14%). Deviations from low-risk treatment were 
also significantly less frequent in centers using stringent risk tools compared to centers using 
unnamed and unvalidated tools (7% versus 19.1%).(1) Although none of the validated rules 
included in this study have been subject to formal implementation and impact analysis, it is 
conceivable that a rule such as SPOG rule, which requires a 24 hours period of observation, may 
result in less failure.(9) 
When implemented at the time of hospital presentation with FN, the sensitivity of a CDR to 
predict infection or adverse event is considered to be of greatest importance. While this is 
traditionally at the expense of specificity, the ability of the test to correctly identify those without 
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the disease needs to be sufficiently high to make implementation of the rule worthwhile. Our 
validation study has identified five internationally derived pediatric FN CDRs that are 
reproducible. However, although reproducibility was observed in these studies, not all can be 
recommended for implementation based on either inadequate sensitivity or failure to identify a 
sufficient number of patients that are low risk. Of the rules validated in this study, the SPOG rule 
arguably exhibits the best balance between sensitivity and specificity in our population and may 
facilitate the implementation of a low-risk FN program that is safe, practical and will avoid the 
over treatment of as many children as possible. Further research is required to assess the clinical, 
psychosocial and economic impact of such a program and to ensure the strengths and the 
weakness of the CDR continue to be evaluated. 
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Figure 1. Forest plot showing sensitivity with 95% confidence intervals for derivation studies, 
validation cohort and restricted validation cohort  
Figure 2. Forest plot showing specificity with 95% confidence intervals for derivation studies, 
validation cohort and restricted validation cohort  
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Table 1. Comparison of clinical decision rule inclusion and exclusion criteria, variables and outcomes 
Rule Inclusion criteria Exclusion 
criteria 
High risk criteria High risk outcome 
Validation 
cohort(10) 
Cancer or haematological 
PDOLJQDQF\IHYHU38.0°C 
RQFH$1&
1000cells/mm3; outpatient 
Receiving 
antibiotics; 
inpatient onset 
FN 
 
NA NA 
SPOG(9) Cancer or haematological 
PDOLJQDQF\IHYHU38.5°C 
onFHRU&GXULQJ
hours^$1&
500cells/mm3; outpatient 
Myeloablative 
chemotherapy; 
AE known at 
presentation 
Applied after 24 hours. Total score 
 KLJKULVNRI$( 
 
Score for preceding chemotherapy 
more intensive than ALL 
maintenance =4; Hb ; 
Adverse outcome ± defined as a SMC 
(death, complication requiring ICU and 
potentially life-threatening complication 
as judged by the treating physician) as a 
result of infection, MDI (positive 
bacterial or fungal culture from a 
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leukocyte count < 0.3 G/L=3; 
platelet <50 G/L=3 
normally sterile site and detection of a 
viral antigen by PCR) and 
radiologically confirmed pneumonia. 
Bacteraemia not defined 
Hakim(21) 
 
Cancer or haematological 
PDOLJQDQF\IHYHU38.3°C 
RU&IRUKRXUA; 
$1&FHOOVPP3; 
outpatient 
HSCT; inpatient 
onset FN  
7RWDOVFRUH KLJKULVNRI
invasive bacterial infection. 
 
Score for cancer diagnosis: 
AML=20, ALL/lymphoma=7, 
solids=0 points; Clinical 
presentation serious unwell or toxic 
 SRLQWV)HYHU&DW
presentation = 11 points; ANC<100 
= 10 points 
Proven invasive bacterial infection ± 
defined as isolation of a pathogen from 
a sterile body site or as proven by 
histology. Culture-negative sepsis ± 
defined as a systemic response to a 
possible infection because of 
hemodynamic instability, focal or 
multiple organ involvement or altered 
mental status or lethargy.  
Bacteraemia defined as a recognized 
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 pathogen cultured from one or more 
blood cultures or common commensals 
cultured from two or more blood 
cultures. 
Alexander 
(22) 
Cancer or haematological 
malignancy, fever >38.5°C 
at presentation or within 6h; 
$1&FHOOVPP3; 
outpatient 
Previous HSCT, 
inpatient onset 
FN 
Any of following = high risk AE. 
AML, Burkitt lymphoma, ALL in 
induction, progressive or relapsed 
disease; Hypotension, 
tachypnea/hypoxia 94%; new CXR 
changes; altered mental status; 
severe mucositis; vomiting or 
abdominal pain; focal infection; 
other clinical reason for in-patient 
treatment 
Adverse outcome ± defined as 
identification of a pathogen 
(bacteraemia not defined)* or where 
there was a SMC* or death 
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Klaassen(24) Cancer or haematological 
malignancy, fever > 38.5°C 
once or > 38.0°C during 12 
hour period^$1&RU
between 0.5 and 1.0 
cells/mm3 and expected to 
fall, outpatient 
New diagnosis 
cancer, HSCT 
within 6 months, 
comorbidity on 
presentation inc 
severe mucositis 
and pneumonia 
AMC < 100 cells/m3 Significant bacterial infection ± defined 
as blood or urine culture positive for 
bacteria, interstitial or lobar 
consolidation on CXR, or unexpected 
death from infection (patient not 
palliative) 
 
Baorto(23) 
 
Cancer or haematological 
PDOLJQDQF\IHYHU38.0°C; 
$1&FHOOVPP3 
Age <1y, 
previous HSCT 
AMC < 155 cells/m3 Bacteraemia (not defined)* 
 
 
Rackoff(25) Cancer or haematological 
PDOLJQDQF\IHYHU38.5°C 
once or 38.0°C 3x during a 
24h period^; ANC < 
Inpatient onset 
FN 
AMC < 100 cells/m3 and 
temperature °C. 
 
/RZULVN $0&FHOOVP3; 
Bacteraemia ± defined as a positive 
blood culture* 
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500cells/mm3; outpatient intermediate risk = AMC <100 
cells/m3 and temperature <39°C; 
HSCT, haematopoietic stem cell transplant; SMC, serious medical complication; ICU, intensive care unit; MDI, microbiologically defined 
infection; PCR, polymerase chain reaction; AMC, absolute monocyte count 
*international consensus definition used for validation(13); ^GXHWRDYDLODEOHGDWDWKLVGHILQLWLRQZDVPRGLILHGIRUYDOLGDWLRQWR&RQFHDV
per existing dataset 
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Table 2. Sensitivity, specificity, positive predictive value and negative predictive value of derivation study (d) and validation cohort (v) and 
restricted validation cohort (Rv).  
Rule 
 
Epi-
sodes 
Out-
come  
n (%) 
LR 
n (%) 
True 
pos 
True 
neg 
False 
pos 
False 
neg 
Sensitivity 
 
Specificity 
 
PPV, % 
(95% CI) 
NPV, % 
(95% CI) 
%  
(95% CI) 
Dif from 
derivation 
% 
(p value) 
%  
(95% CI) 
Dif from 
derivation
% 
(p value) 
Rules predicting infection and adverse outcome (refer to table 1 for specific definitions) 
d-SPOG(9)  423  122 
(28.2) 
165 
(39) 
112* 155 146 10 91.8 (85.6-
95.5) 
 51.1 (45.9-
57.1) 
 43.3 (37.5-
49.5) 
93.9 (89.2-
96.7) 
v-SPOG 
 
650 168 
(25.8) 
289 
(44.4) 
131* 223 259 37 78.0 (71.1-
83.6) 
13.8 
(0.002) 
46.3 (41.9-
50.7) 
5.2 (0.16) 33.6 (29.1-
38.4) 
85.8 (81.0-
89.5) 
Rv-SPOG  561 149 244 119* 188 224 30 79.9 (72.7- 11.9 45.6 (40.9- 5.9 (0.13) 34.7 (29.9- 86.2 (81-
A
C
C
E
P
TE
D
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
27 
 
(26.6) (43.5) 85.6) (0.006) 50.5) 39.9) 90.2) 
d-
Hakim(21) 
 
323  47 (14.6) 223 
(69) 
35 211 65 12 74.5 (60.5-
84.7) 
 76.4 (71.1-
81.1) 
 35 (26.4-
44.7) 
94.6 (90.8-
96.9) 
v-Hakim 
 
650 90 (13.8) 565 
(86.9) 
30 505 55 60 33.3 (24.5-
43.6) 
41.1 
(<0.001) 
90.2 (87.4-
92.4) 
13.7 
(<0.001) 
35.3 (26-
45.9) 
89.4 (86.6-
91.7) 
Rv-Hakim 
 
542 78 (14.4) 462 
(85.2) 
28 412 52 50 35.9 (26.1-
47) 
38.6 
(<0.001) 
88.8 (85.6-
91.4) 
12.3 
(<0.001) 
35 (25.5-
45.9) 
89.2 (86-
91.7) 
d-
Alexander(
22) 
104 22 (21.2) 55 (53) 20 53 
 
29 2 90.9 (72.2-
98.4) 
 64.6 (53.8-
74.1) 
 40.8 (28.2-
54.8) 
96.4 (87.7-
99.4) 
v-
Alexander 
650 162 
(24.9) 
307 
(47.2) 
114 259 229 47 70.8 (63.4-
77.3) 
20.1 (0.07) 53.1 (48.6-
57.5) 
11.6 (0.06) 33.2 (28.5-
38.4) 
84.6 (80.2-
88.2) 
Rv- 342 96 (28) 160 69 133 113 27 71.9 (62.2- 19 (0.10) 54.1 (47.8- 10.6 (0.12) 37.9 (31.2- 83.1 (76.6-
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Alexander  (46.8) 79.9) 60.2) 45.1) 88.1) 
d-
Klaassen(2
4) 
227  43 (18.9) 83 
(36.6) 
36 76 107 7 83.7 (70-
91.9) 
 41.5 (34.6-
48.8) 
 25.3 (18.8-
32.9) 
91.6 (83.6-
95.9) 
v-Klaassen 
 
650 108 
(16.6) 
169 
(26) 
91 152 390 17 84.3 (76.2-
89.9) 
0.5 
(>0.99) 
28.0 (24.4-
32.0) 
13.5 
(<0.001) 
18.9 (15.7-
22.7) 
89.9 (84.5-
93.6) 
Rv-
Klaassen 
634 104 
(16.4) 
168 
(26.5) 
87 151 379 17 83.7 (75.4-
89.5) 
0.1 
(>0.99) 
28.5 (24.8-
32.5) 
13.0 
(<0.001) 
18.7 (15.4-
22.5) 
89.9 (84.4-
93.6) 
Rules predicting bacteraemia 
d-
Baorto(23) 
1171 189 
(16.1) 
164 
(14) 
179 154 828 10 
 
94.7 (90.5-
97.1) 
 15.7 (13.5-
18.1) 
 17.8 (15.5-
20.3) 
93.9 (89.1-
96.7) 
v-Baorto 
 
650 61 (9.4)^ 122 
(18.8) 
59 120 469 2 96.7 (88.8-
99.4) 
2.0 (0.74) 20.4 (17.3-
23.8) 
4.7 (0.02) 11.2 (8.7-
14.1) 
98.4 (94.2-
99.7) 
Rv-Baorto 535 54 83 54 83 398 0 100 (93.4- 5.3 (0.12) 17.3 (14.1- 1.6 (0.45) 11.9 (9.3- 100 (95.6-
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(10.1)^ (15.5)  100) 20.9) 15.3) 100) 
d-
Rackoff(25
) 
115  24 (20.9) 94 
(81.7) 
10 80 11 14 41.7 (24.5-
61.2) 
 87.9 (79.6-
93.1) 
 47.6 (28.3-
67.6) 
85.1 (76.5-
90.9) 
v-Rackoff 
 
650 61 (9.4)^ 524 
(80.6) 
20 483 106 41 32.8 (22.3-
45.3) 
8.9 (0.46) 82.0 (78.7-
84.9) 
5.9 (0.18) 15.9 (10.5-
23.2) 
92.2 (89.6-
94.2) 
Rv-
Rackoff 
 
556 57 
(10.3)^ 
444 
(79.9) 
19 406 93 38 33.3 (22.5-
46.3) 
8.3 (0.61) 81.4 (77.7-
84.5) 
6.5 (0.18) 17 (11.1-
25) 
91.4 (88.5-
93.7) 
d, derivation study; v, validation using inclusion/exclusion criteria from existing dataset(10); Rv, validation restricted to inclusion/exclusion 
criteria from derivation study; LR, low risk; pos, positive; neg, negative; CI, confidence interval; PPV, positive predictive value; NPV, negative 
predictive value; Dif, difference.  
*includes episodes with adverse event known at reassessment; ^statistically significant difference in outcome as compared to derivation study. 
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Figure 1 
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Figure 2 
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